“Buzz on the Street” Show: Nemaura Medical (NASDAQ: NMRD) Granted UK Trademark “Meta Score” | Financial Buzz

“Buzz on the Street” Show: Nemaura Medical (NASDAQ: NMRD) Granted UK Trademark “Meta Score”

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Nemaura Medical Granted UK Trademark “Meta Score,” a Digital Biomarker Term for its Metabolic Health Program.”

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today announced that it has been granted a UK trademark for “Meta Score,” a term the Company plans to use as a digital biomarker for its consumer metabolic health program. Trademark applications are now pending in several other major global territories.

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!